Figure 1. Characterization of RCC patient EVs and their impact on RCC cells. (A) RNA extracted from the RCC patient and healthy control EVs were subjected to qPCR analysis to evaluate the expression of miR-155. Levels of miR-155 increased in the RCC patient EVs. (B) The viability of 786-O or Caki-1 cells upon EV treatment was measured by CCK8 assay. RCC patient EVs increased cell viability. (C) The expression of miR-155 in 786-O or Caki-1 cells was determined by qRT-PCR after EV treatment. RCC patient EVs elevated miR-155 levels. (D) 786-O or Caki-1c cells were used in a wound-healing migration assay in the presence of different EVs. The migrated cells were observed under a microscope for 12 h. RCC patient EVs enhanced cell migration. (E) The apoptosis of 786-O or Caki-1 was measured by flow cytometry, revealing that RCC patient EVs significantly inhibited apoptosis. This experiment was conducted using three distinct biological replicates. *P < 0.05, **P < 0.01 and ***P < 0.001.